6/24
02:09 pm
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $50.00 price target on the stock.
Medium
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $50.00 price target on the stock.
6/17
08:05 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
High
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
6/17
05:49 am
rnac
Correction: Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes [Yahoo! Finance]
High
Report
Correction: Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes [Yahoo! Finance]
6/17
05:37 am
rnac
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes [Yahoo! Finance]
High
Report
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes [Yahoo! Finance]
6/14
02:02 pm
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $50.00 price target on the stock.
Low
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $50.00 price target on the stock.
6/6
07:05 am
rnac
Cartesian Therapeutics Announces New Employment Inducement Grant
High
Report
Cartesian Therapeutics Announces New Employment Inducement Grant
6/4
08:13 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock.
Low
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock.
5/24
08:03 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at Mizuho. They set a "buy" rating and a $40.00 price target on the stock.
Medium
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at Mizuho. They set a "buy" rating and a $40.00 price target on the stock.
5/23
02:01 pm
rnac
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08 [Yahoo! Finance]
Medium
Report
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08 [Yahoo! Finance]
5/23
08:01 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
Medium
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
5/22
07:11 am
rnac
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis [Yahoo! Finance]
Low
Report
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis [Yahoo! Finance]
5/22
07:00 am
rnac
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Low
Report
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
5/13
04:30 pm
rnac
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
High
Report
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
5/13
01:48 pm
rnac
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock [Yahoo! Finance]
Low
Report
What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock [Yahoo! Finance]
5/9
03:39 pm
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
Low
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
5/8
11:53 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.
Low
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.
5/8
07:08 am
rnac
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/8
07:00 am
rnac
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Low
Report
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
5/6
04:15 pm
rnac
Cartesian Therapeutics Announces New Employment Inducement Grants
Medium
Report
Cartesian Therapeutics Announces New Employment Inducement Grants
4/25
11:44 am
rnac
Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade [Yahoo! Finance]
Low
Report
Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade [Yahoo! Finance]
4/24
05:52 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Low
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
4/23
07:02 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target raised by analysts at HC Wainwright from $2.00 to $54.00. They now have a "buy" rating on the stock.
High
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target raised by analysts at HC Wainwright from $2.00 to $54.00. They now have a "buy" rating on the stock.
4/23
07:02 am
rnac
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $39.00 price target on the stock.
High
Report
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $39.00 price target on the stock.
4/22
04:34 pm
rnac
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting [Yahoo! Finance]
High
Report
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting [Yahoo! Finance]
4/22
04:30 pm
rnac
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
High
Report
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting